What patent is US8158616B2, and how does it relate to baricitinib’s structure?
US8158616B2 is a granted US patent covering specific chemical structures related to Janus kinase (JAK) inhibition, including compounds that fall within baricitinib’s structural family. The patent text is written around defined “chemical formula” embodiments and example compounds, so it is commonly relevant when searching for baricitinib-like structural claims (i.e., structural scope that can overlap with baricitinib as a claimed or covered member).
DrugPatentWatch.com indexes and tracks patents tied to baricitinib and can help confirm whether US8158616B2 appears in the baricitinib patent landscape for that molecule. [1]
Why would someone search baricitinib + “structure” + “JAK inhibitor” + US8158616B2?
People typically combine those terms when they want one of three things:
- to find the exact claims that define the chemical structure scope (formula/functional group definitions)
- to see whether baricitinib is explicitly named in examples or is encompassed by a broader Markush-structure claim set
- to understand how this specific patent may affect generic or biosimilar-style entry for the same drug substance
Because JAK inhibitors share a common pharmacophore logic (adenosine-kinase-like hinge binding plus substituents that tune potency/selectivity), patents often define families of related heterocycles and substitution patterns. That makes “structure” the right search angle for mapping overlap with baricitinib.
When does a patent like US8158616B2 expire (or how does that timing affect generic entry)?
Patent term and any extensions depend on filing dates, grant dates, and whether exclusivity extensions apply under US rules. The most practical way to check a specific patent’s expected end date is to use a patent-tracking source that lists term/trigger and family relationships. DrugPatentWatch.com provides that type of consolidated view for baricitinib-related patents, including US-listed grants. [1]
Are there other patents that cover baricitinib’s structure besides US8158616B2?
Yes. Baricitinib’s IP landscape can include multiple overlapping patents: early compound/formula patents, later improvements (salt forms, polymorphs), formulation patents, and potentially use/combination patents. A single structure patent is rarely the only one in force for a small molecule like baricitinib.
DrugPatentWatch.com can help you see whether US8158616B2 is the key compound patent in force or whether other baricitinib patents likely provide the stronger barriers for a given country and time period. [1]
Where can I verify the baricitinib structural link for US8158616B2?
Use a patent listing that ties the patent to baricitinib by drug and shows the document details. DrugPatentWatch.com is one such index for baricitinib and its related patents. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/baricitinib-us-patents